White Rose Research Online
Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
Abstract
BackgroundAdolescents living with HIV have poorer treatment outcomes than other age groups and might benefit from long-acting-injectable (LAI) antiretroviral therapy (ART). We evaluated efficacy and safety of LAI cabotegravir?rilpivirine compared with daily oral ART in adolescents living with HIV with virological suppression in Africa.
Keywords
- HIV-related health complications and treatments
- Human immunodeficiency virus (HIV)
- Antiretroviral therapy
- Population
- Viral load
- Clinical trial
- Sida
- Open access
Source
Published in White Rose Research Online (University of Leeds, The University of Sheffield, University of York). The abstract is shown as published and remains the work of its authors; read the full article at the source.
eprints.whiterose.ac.uk/id/eprint/245711/1/1-s2.0-S0140673626015370-main.pdf
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.